Insulin resistance - What is myth and what is reality?

Acta Endocrinologica

Volumn 7, Issue 1, 2011, Pages 123-145

  Ionescu Tirgoviste C ^a  

^a Institute of Diabetes   (Romania)

Author keywords

Insulin receptor; Insulin resistance sensitivity; Obesity; Type 2 diabetes

Indexed keywords

EID: 79960426151     PISSN: 18410987     EISSN: None     Source Type: Journal    
DOI: 10.4183/aeb.2011.123     Document Type: Note

References (125)

1. Kahn SE, Zraika S, Utzschneider KM, Hull RL. The β-cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 2009; 52:1003-1012
2. Robertson RP. Estimation of β-cell mass by metabolic tests. Necessary, but how sufficient? Diabetes 2007; 56:2420-2424
3. Ionescu-Tirgoviste C. For a new paradigm of diabetes. Rom J Intern Med 2007; 45:3-15
4. Paulescu NC. Recherche sur le role du pancreas dans l'assimilation nutritive. Arh. Int Physiol 1921; 17:85-109
5. Collip JB. The original method as usedfor the isolationof insulin in semipure form for the treatment of the first clinical cases. J Biol. Chem 1922; 15:55-56
6. LeCompte PM, Legg MA. Insulitis (lymphocytic infiltration of pancreatic islets) in late-onset diabetes. Diabetes 1972; 21:762-769
7. Nerup J, Platz P, Andersen OO. HLA antigens and diabetes mellitus. Lancet 1975; ii:864-866
8. Bottazzo GF, Dean BM, McNally JM, MacKay EH, Switt PG, Gamble DR. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas. N Engl J Med 1985; 313:353-359
9. Gale EAM. The discovery of type 1 diabetes. Diabetes 2001; 50:217-226
10. Ionescu-Tîrgoviste C. Proinsulin as the possible key in the pathogenesis of type 1 diabetes. Acta Endocrinologica (Buc) 2009; vol. V, no 2, p.233-249
11. Cerasi E: A la recherche du tempus perdu-epilogue to the Minkowski Award lecture 1974. Diabetologia 1985; 28:547-555
12. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52:102-110
13. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 273:E214-E223
14. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607
15. Falta W, Boller R. Insularer und insulinresistenter diabetes. Klin Wochenschr 1931; 10:438-443
16. Ionescu-Tîrgoviste C., Mincu I., Simionescu M., Cheta D., Mirodon Z., Sîntu E., Popa E., Barnea A. Disappearance rate of insulin antibodies after discontinuing insulin treatment in 32 type 2 (non-insulindependent) diabetic patients. Diabetologia 1984; 27:592-595
17. Himsworth HP. The mechanism of diabetes mellitus. Lancet 1939; 2, 1
18. Grigorescu F, Flier JS, Kahn CR. Defect in insulin receptor phosphorylation in erythrocytes and fibroblasts associated with severe insulin resistance. J Biol Chem 1984; 259:15003-5006
19. Seino S, Seino M, Bell G.I. Human insulin-receptor gene. Diabetes 1990; 39:129-133
20. Savage DB, S, O'Rahilly. Leptin theraphy in lipodysrophy. Diabetologia 2010; 53:7-9
21. Kotronen A, Seppälä-Lindroos A, Bergholm R, Yhi-Jarvinen H. Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome. Diabetologia 2008; 51:130-138
22. Reaven GM. The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 2006; 83:1237-1247
23. Stern ES, Williams K, Ferrannini E, DeFronzo RA, Bogardus C, Stern MP. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 2005; 54:333-339
24. Toledo FG, Menshikova EV, Ritov VB, Azuma K, Radikova Z, DeLany J, Kelley DE. Effects of physical acitivity and weight loss on skeletal muscle mitochondria and relationship with glucose control in type 2 diabetes. Diabetes 2007; 56:2142-2147
25. Ionescu-Tîrgoviste C, Cheta D, Popa E, Mincu I. Le role de l'obesité dans l'etiopathogenie du diabete sucre. Medecine et Nutrition 1976; 12:97-106
26. DeFronzo RA, Tripathy D: Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 2009; Vol. 32, Supl 2
27. Morris DL, Cho KW, Zhou Y, Rui L. SH2B1 enchances insulin sensitivity by both stimulating the insulin receptor and inhibiting tyrosine dephosphorylation of insulin receptor substrate proteins. Diabetes 2009; 58:2039-2047
28. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 1998; 32:S157-S163
29. Kahn SE, Porte D Jr. The pathophysiology and genetics of type 2 diabetes mellitus. (In:) Porte D Jr., Sherwin RS, Baron A.: Ellenberg &Rifkin's Diabetes Mellitus. Sixth edition. New York, Chicago, San Francisco, McGraw-Hill 2003; pp.331-365
30. Singh S, Loke YK, Furberg CD. Longterm risk of cardiovascular events with rosiglitazone. A meta-analysis. JAMA 2007; 298(10):1189-1195
31. Lipska K.J., Ross J.S.: Switching from Rosiglitazone. Thinking Outside the Class. JAMA 2011, E1-E2
32. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J. Clin. Invest. 1960; 41:2173-2180
33. Rabinowitz D, Zierler KJ. Forearm metabolism in obesity and its response to intra-arterial insulin. Characterization of insulin resistance and evidence for adaptive hyperinsulinemia. J. Clin. Invest. 1962; 41:2173-2181
34. Ionescu-Tîrgoviste C, Guja C. Proinsulin, proamylin and the β-cell endoplasmic reticulum: The key for the pathogenesis of different diabetes phenotypes. Proc. Rom. Acad. 2007; Series B, 2, p. 113-139
35. Shanik MH, XuY, Skrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care 2008; 31(2):S262-S268
36. Gerich JE. Contributions of insulinresistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clinic Proc 2003; 78:447-456
37. Li C, Ford ES, McGuire LC, Mokdad AH, Little RR, Reaven GM. Trends in hyperinsulinemia among nondiabetic adults in the U.S. Diab. Care 2006; 29:2396-2402
38. Temple RC, Clark PM, Nagi DK, Schneider AE, Yudkin JS, Hales CN. Radioimmunoassay may overestimate insulin in non-insulin-dependent diabetics. Clin Endocrinol 1990; (Oxf)32:689-693
39. Iozzo P. Viewpoints on the way to a consensus session. Where does insulin resistance start? The adipose tissue. Diebetes Care 2009; 32(suppl 2):S168-S173
40. Laasko M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms. Diabetes Care 2010; 33, 2:442-449
41. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, Shitrit A, Fuchs Z. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. Hypertension 1985; 75:1514
42. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type 2 diabetes in the offspring of diabetic parents. Ann. Int. Med. 1990; 113:909-915
43. O'Rahilly S, Farooqi IS. Human Obesity: A heritable neurobehavioral disorder that is highly sensitive to environmental conditions. Diabetes 2008; 57:2905-2910
44. Ferrannini E, Mari A. How to measure insulin sesnsitivity. J Hypertens 1998; 16:895-906
45. Bonora E, Moghetti P, Zancanaro C. Estimates of in vivo insulin resistance action in man: comparison of insulin tolerance tests with euglycaemic and hyperglycaemic glucose clamp studies. J Clin Endocrinol Metab 1989; 68:374-378
46. Hansen T, Drivsholm T, Urhammer SA, Palacios RT, Volund A, Borch-Johnsen K, Pedersen O. The BIGTT test. A novel test for simultaneous measurement of pancreatic β-cell function, insulin sensitivity, and glucose tolerance. Diabetes Care 2007; 30:257-262
47. Matsuda M. Measuring and estimating insulin resistance in clinical and research settings. Nutrition, Metabolism & Cardiovascular Diseases 2009; 20:1-8
48. Ionescu-Tîrgoviste C, Ioacara S, Guja C. A pathophysiological approach to metabolic syndrome using factor analysis in an adult Romanian population. Arch. Physiol. Biochem. 2006; 112:182-188
49. Robertson RP. Estimation of β-cell mass by metabolic tests. Necessary, but how sufficient? Diabetes 2007; 56:2420-2424
50. Adler AI, Levy JC, Matthews DR, Stratton IM, Hines G, Holman RR. Insulin sensitivity at diagnosis of type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS33). Diabet Med 2005; 22:306-311
51. Cull CA, Jensen CC, Retnakaran R. Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: UK Prospective Diabetes Study 78. Circulation 2007; 116:2119-2126
52. Ogilvie RF. The islands of Langerhans in 19 cases of obesity. J. Pathol. Bacteriol. 1933; 37:473-481
53. Ogilvie RF. Quantitative estimation of pancreatic islet tissue. Quart. J. Med. 1937; 6, 287
54. Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv. Synth. Pathol. Res. 1985; 4:110-125
55. Yoon KH, Ko SH, Cho SH, Lee JM, Ahn YB, Song KH, Yoo SJ, Kang MI, Cha BY, Lee KW, Son HY, Kang Sk, Kim HS, Lee IK, Bonner-Weir S. Selective β-cell loss and alpha-cell expansion in patients with Type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab. 2003; 88:2300-2308
56. Godsland IF, Jeffs JAR, Johnston DG. Loss of LLcell function as fasting glucose increases in the non-diabetic range. Diabetologia 2004; 47:1157-1166
57. Ionescu-Tîrgoviste C, Guja C, Vladica M et al. Plasma proinsulin could be a marker of β-cell dysfunction in both type 1 and type 2 diabetes (Abstract). Acta Diabetologica Rom. 2005; 31:22-23
58. Mari A, Ferrannini E. Insulin secretion and impaired glucose tolerance. Reply to Jenkins AB, Campbell LV (letter). Diabetologia. 2010; 53:2269-2270 (Letter)
59. Cuatrecasas P, Desbuquois B, Krug F. Insulin receptor interactions in liver cell membranes. Biochem. Biophys. Res. Commun. 1971; 44:333-39
60. Freychet P. MicroRNAs: novel players in the regulation of iicell function and lipid metabolism. Int J Metab Fax X, 33, 2007
61. Joshi RL, Lamothe B, Cordonnier N, Mesbah K, Monthioux E, Jami J, Bucchini D. Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality. EMBO J 1996; 15:1542-1547
62. Accili D. The struggle for mastery in insulin action: from Triumvirate to Republic. Diabetes 2004; 53:1633-1643
63. Hawkins M, Rossetti L. Insulin resistance and its role in the pathogenesis of type 2 diabetes. [In:] Joslin's Diabetes Mellitus. Selected Chapters from the Fourteenth Edition. Edited by C. Ronald Kahn, Gordon C. weir, George L. King et al. Philadelphia, Baltimore, New York,. Lippincott, Williams &Wilkins 2005; pp 445-448
64. Støy J, Edghill EL, Flanagan SE, Ye H, Paz VP, Pluzhnikov A, Below JE, Hayes MG, Cox NJ, Lipkind GM, Lipton RB, Greeley SA, Patch AM, Ellard S, Steiner DF, Hattersley AT, Philipson LH, Bell GI. Insulin gene mutations as a cause of permanent neonatal diabetes. PNAS 2007; vol. 104, 38:15040-15044
65. Grigorescu F, Flier JS, Kahn CR. Characterization of binding and phosphorylation defects of erythrocyte insulin receptors in type a syndrome of insulin resistance. Diabetes 1986; 35:127-38
66. Rosen OM. After insulin binds. Science 1987; 237:1452-58
67. Taylor SI. Insulin action, insulin resistance, and type 2 diabetes mellitus. In: Scriver C.R., Beaudet A.L., Sly W.S. The metabolic and molecular bases of inherited disease, 8th ed. New York; McGraw-Hill 2000; pp. 1433-1470
68. Muller-Wieland D, Taub R, Tewari DS, Kriauciunas KM, Sethu S, Reddy K, Kahn CR. Insulin-receptor gene and its expression in patients with insulin resistance. Diabetes 1989; 38:31-38
69. American Diabetes Association. Consensus development conference on insulin resistance. Diabetes Care 1998; 21:310-314
70. Cox NJ, Epstein PA, Spielman RS. Linkage studies on NIDDM and the insulin and insulin-receptor genes. Diabetes 1989; 38:653-658
71. Ullrich A, Bell JR, Chen EY, Herrere R, Petruzzelli LM, Dull TJ, Gray A, Coussens L, Liao YC, Tsubokawa M. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature (Lond) 1985; 313:756-61
72. Marliss EB. Protein in diabetes and obesity: realy for prime time. Diabetic Med 2006; 23(Suppl. 4):411-607
73. Ferrannini E, Mari A. How to measure insulin sesnsitivity. J Hypertens 1998; 16:895-90
74. Scwartz B, Jacobs DR Jr, Moran A, Steinberger J, Hong CP, Sinaiko AR. Measurement of insulin sensitivity in children: comparison between the euglycemic-hyperinsulinemic clamp and surrogate measures. Diabetes Care 2008; 31:783-788
75. Ayala J, Bracy D, McGuinness OP, Wasserman DH. Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 2006; 55(2):390-397
76. Wassermann DH, Ayala JE, McGuinness OP. Lost in translation. Diabetes 2009; 58:1947-1950
77. Swinnen SGHA, Holleman F, DeVries JH. The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. Diabetologia 2008; 51:1790-1795
78. Bergmann RN, Ider YZ, Bowden CR et al. Quantitative assessment of insulin sensitivity. Am J Physiol 1979; 236:E667-E677
79. Bergman RN. Toward physiological understanding of glucose tolerance: minimal model approach. Diabetes 1989; 38:1512-1527
80. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419
81. Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebocontrolled randomized study. Diabet Med 2004; 21:568-576
82. Morris AD, Ueda S, Petrie JR, Connell JM, Elliott HL, Donnelly R. The euglicaemic hyperinsulinemic clamp: an evaluation of current methodology. Clin. Exp. Pharmacol. Physiol. (Australia) 1997; 24:513-518
83. Haffner SM. The insulin resistance syndrome revisited. Diabetes Care 1996; 19:275-27
84. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003; 139:802-809
85. Meigs JB. Metabolic syndrome. In search of a clinical role. Diabetes Care 2004; 27:2761-2763
86. Stern MP, Williams K, Gonzales-Villalpando C et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular diseases? Diabetes Care 2004; 27:2676-2681
87. Gale EA. The myth of the metabolic syndrome. Diabetologia 2005; 48:1679-1683
88. Davidson MB. Does the metabolic syndrome exist? Response to Grundy. Diabetes Care 2006; 29:2565
89. Yudkin JS. Insulin resistance and the metabolic syndrome-or the pitfalls of epidemiology. Diabetologia 2007; 50:1576-1586
90. Simmons RK, Alberti KG, Gale EA, Colagiuri S, Tuomilehto J, Qiao Q, Ramachandran A, Tajima N, Brajkovich Mirchov I, Ben-Nakhi A, Reaven G, Hama Sambo B, Mendis S, Roglic G. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2010; 53:600-605
91. Borch-Johansen K, Wareham N. The rise and the fall of the metabolic syndrome. Diabetologia 2010; 53:597-599
92. Perseghin G. Where thas insulin resistance start? The liver. Diabetes Care 2009; 32(suppl 2):S164-S167
93. Marchetti P, Lupi R, Del Guerra S, Bugliani M, D'Aleo V, Occhipinti M, Boggi U, Marselli L, Masini M. Goals of treatment for type 2 diabetes; β-cell preservation for glycemic control. Diabetes Care 2009; 32(Suppl 2):S178-S183
94. Pagatto U. Where does insulin resistance start? The brain. Diabetes Care 2009; 32(Suppl 2):S174-S177
95. Cohen DA. Neurophysiological pathways to obesity: below awareness and beyond individual control. Diabetes 2008; 57:1768-1773
96. Rauchfuss S, Geiger J, Walter U, Renne T, Gambaryan S. Insulin inhibition of platelet-endithelial interaction is mediated by insulin effects on endothelial cells without direct effects on platelets. J Thromb Haemost 2008; 6:856-864
97. Draznin B. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85?: the two sides of a coin. Diabetes 2006; 55:2392-2397
98. Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, Lauro R. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J. 2001; 15:2099-2111
99. Almind K, Inaue G, Pedersen O, Kahn CR. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J. Clin. Invest. 1996; 97:2569-2575
100. Jellema A, Zeegers MP, Feskens EJ. Gly 972Arg variant in the insulin receptor substrate-1 gene and association with type 2 diabetes: a meta-analysis of 27 studies. Diabetologia 2003; 46:990-995
101. Zeggini E, Parkinson J, Halford S, Owen KR, Frayling TM, Walker M, Hitman GA, Levy JC, Sampson MJ, Feskens EJ, Hattersley AT, McCarthy MI. Association studies of insulin receptor substrate 1 gene (IRS1) variants in type 2 diabetes samples enriched for family history and early age of onset. Diabetes 2004; 53:3319-3322
102. Morini E, Prudente S, Succurro M, Chandalia M, Zhang YY, Mammarella S, Pellegrini F, Powers C, Proto V, Dallapiccola B, Cama A, Sesti G, Abate N, Doria A, Trischitta V. IRS1 G972R polymorphism and type 2 diabetes: a paradigm for the difficult ascertainment of the contribution to disease susceptibility of "low-frequency-low-risk"variants. Diabetologia 2009; 52:1852-1857
103. Grigorescu F, Attaoua R, Ait El Mlkadem S, Beleza S. Haplogendis initiative-SICA. Acta Endocrinologica 2009; vol V, 1: 143-148
104. Krook A, Zierath JR. Specificity of insulin signaling in human skeletal musle as revealed by small interfering RNA. Diabetologia 2009; 52:1231-1239
105. Nauk MA, Vilsboll T, Gallwitz B, Garber A, Madsbad S. Incretin-Based Therapies: viewpoints on the way to consensus. Diabetes Care 2009; 32:S223-S231
106. Kim J, Montagnani M, Koh KK, Quon MJ. Reciprocal relationship between insulin resistance and endothelial dysfunction. Molecular and pathophysiological mechanism. Circulation 2010; 18:1888-1904
107. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metabolism 2008; 7:95-96
108. Escribamo O, Guillen C, Nevado C, Gómez-Hernández A, Kahn CR, Benito M. β-cell hyperplasia induced by hepatic insulin resistance. Role of a liver-pancreas endocrine axis through insulin receptor a isoform. Diabetes 2009; 58:820-828
109. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N. Engl. J. Med. 2004; 350:664-671
110. Morino K, Petersen KF, Dufour S, Befroy D, Frattini J, Shatzkes N, Neschen S, White MF, Bilz S, Sono S, Pypaert M, Shulman GI.: Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulinresistant offspring of type 2 diabetic parents. J Clin Invest 2005; 115:3587-3593
111. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444:840-846
112. Szendroedi J, Roden M. Mitochondrial fitness and insulin sensitivity in humans. Diabetologia 2008; 51:2155-2167
113. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005; 307:384-387
114. Bagdage JD. Basal insulin and obesity. Lancet 1968; 2,630
115. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003; 144:5159-5165
116. del Prato S. Role of glucotoxicity and lipotoxicity in the pathophysiology of type 2 diabetes mellitus and emerging treatment strategies. Diabetes UK. Diabetic Medicine 2009; 26:1185-1192
117. Sims EA, Horton ES. Endocrine and metabolic adaptation to obesity and starvation. Am. J. Clin. Nutr. 1968; 21, 1455
118. Goran M, Lane C, Toledo-Corral C et al. Persistence of pre-diabetes in overweight and obese hispanic children. Association with progressive insulin resistance, poor-cell function, and increasing visceral fat. Diabetes 2008;57:3007-3012
119. Cnop M, Hughes SJ, Igoillo-Esteve M, Hoppa MB, Sayyed F, van de Laar L, Gunter JH, de Koning EJP, Walls GV, Gray DWG, Johnson PRV, Hansen BC, Morris JF, Pipeleers-Marichal M, Cnop I, Clark A. The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation. Diabetologia. 2010; 53:321-330
120. McCarthy MI, Abecasis GR, Cardon LR et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008; 9:356-369
121. Van Hoek M, Dehgan A, Witteman JCM et al. Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study. Diabetes 2008; 57:3122-3128
122. Florez JC. Newly identified loci highlight β-cell distruction of a key cause of type 2 diabetes: where are the insulin resistance genes? Diabetologia 2008; 51:1100-1110
123. Torres AJ, Sanchez-Pernaute A, Cabrerizo L et al. "Metabolic surgery". Obesity and Metabolism 2009; 5(Suppl. To No.2):80-85
124. Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and β-cell function in type 2 diabetes. Diabetes Care 2009; 32:514-520
125. Jenkins AB, Campbell LV. Insulin secretion and impaired glucose tolerance. Diabetologia. 2010; 53:2266-2268 (Letter)